|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Training Set**  **N = 18,281** | | | **Validation Set**  **N = 2,592** | | | **Test Set**  **N = 5,067** | | |
| **Categories** | | **Cirrhosis**  **N=3,665** | **Control**  **N=14,616** | **p-value** | **Cirrhosis**  **N=532** | **Control**  **N=2,060** | **p-value** | **Cirrhosis**  **N=1,015** | **Control**  **N=4,052** | **p-value** |
| **Sex** | **F** | 1,273 (34.7%) | 5,115 (35.0%) | 0.77 | 178 (33.5%) | 695 (33.7%) | 0.90 | 350 (34.5%) | 1,397 (34.5%) | 0.96 |
| **M** | 2,392 (65.3%) | 9,501 (65.0%) | 354 (66.5%) | 1365 (66.3%) | 665 (65.5%) | 2,655 (65.5%) |
| **Age** | **Median**  **(Q1,Q3)** | 57.0  (50.0,63.0) | 57.0  (50.0,63.0) | 0.73 | 57.0  (50.0,62.0) | 57.0  (50.0,63.0) | 0.43 | 57.0  (50.0,63.0) | 57.0  (50.0,63.0) | 0.89 |
| **Mean**  **(SD)** | 55.77 (10.0) | 55.71 (10.09) | 55.03 (10.92) | 55.44 (10.48) | 55.47 (10.30) | 55.52 (10.39) |
| **Cardiovascular disease** | | 330  (9.0%) | 1,681  (11.5%) | <0.01 | 45  (8.5%) | 250  (12.1%) | <0.01 | 83  (8.2%) | 456  (11.3%) | <0.01 |
| **Diabetes mellitus** | | 1,264  (34.5%) | 2,078  (14.2%) | <0.01 | 178 (33.5%) | 281 (13.6%) | <0.01 | 351 (34.6%) | 569 (14.0%) | <0.01 |
| **Hypertension** | | 1,589  (43.4%) | 5,784  (39.6%) | <0.01 | 245 (46.1%) | 824 (40.0%) | 0.01 | 434 (42.8%) | 1589 (39.2%) | 0.04 |
| **Chronic lung disease** | | 667  (18.2%) | 2,463  (16.9%) | 0.05 | 96  (18.0%) | 338 (16.4%) | 0.37 | 192 (18.9%) | 651  (16.1%) | 0.03 |
| **Chronic kidney disease** | | 975  (26.6%) | 1032  (7.1%) | <0.01 | 149 (28.0%) | 135  (6.6%) | <0.01 | 281 (27.7%) | 286  (7.1%) | <0.01 |
| **Alcohol-related liver disease** | | 941  (25.7%) | 0  (0.0%) | <0.01 | 139  (26.1%) | 0  (0.0%) | <0.01 | 257  (25.3%) | 0  (0.0%) | <0.01 |
| **NASH** | | 682  (18.6%) | 0  (0.0%) | <0.01 | 99  (18.6%) | 0  (0.0%) | <0.01 | 185  (18.2%) | 0  (0.0%) | <0.01 |
| **Viral Hepatitis (HBV/HCV)** | | 1,345  (36.7%) | 0  (0.0%) | <0.01 | 178  (33.5%) | 0  (0.0%) | <0.01 | 406  (40.0%) | 0  (0.0%) | <0.01 |
| **Biliary**  **(PBC/PSC)** | | 461  (12.6%) | 0  (0.0%) | <0.01 | 75  (14.1%) | 0  (0.0%) | <0.01 | 120  (11.8%) | 0  (0.0%) | <0.01 |
| **Autoimmune hepatitis** | | 129  (3.5%) | 0  (0.0%) | <0.01 | 28  (5.3%) | 0  (0.0%) | <0.01 | 47  (4.6%) | 0  (0.0%) | <0.01 |
| **Hereditary/Genetic**  **(A1ATD, HH, WD)** | | 196  (5.3%) | 0  (0.0%) | <0.01 | 24  (4.5%) | 0  (0.0%) | <0.01 | 53  (5.2%) | 0  (0.0%) | <0.01 |
| **Cryptogenic** | | 171  (4.7%) | 0  (0.0%) | <0.01 | 19  (3.6%) | 0  (0.0%) | <0.01 | 48  (4.7%) | 0  (0.0%) | <0.01 |
| **Hepatocellular carcinoma** | | 1,000 (27.3%) | 0  (0.0%) | <0.01 | 136  (25.6%) | 0  (0.0%) | <0.01 | 277  (27.3%) | 0  (0.0%) | <0.01 |
| **Other liver diseases** | | 209  (5.7%) | 0  (0.0%) | <0.01 | 35  (6.6%) | 0  (0.0%) | <0.01 | 58  (5.7%) | 0  (0.0%) | <0.01 |
| **MELD Score** | **Median**  **(Q1,Q3)** | 18.0  (13.0,24.0) | N/A |  | 17.5  (13.0,24.0) | N/A |  | 18.0  (12.0,24.0) | N/A |  |
| **Mean**  **(SD)** | 19.21  (8.53) | N/A |  | 18.93  (8.36) | N/A |  | 19.14  (8.61) | N/A |  |

Abbreviations: A1ATD = alpha-1-antitrypsin deficiency; HBV = hepatitis B virus; HCV = hepatitis C virus; HH = hereditary hemochromatosis; PBC = primary biliary cholangitis; PSC = primary sclerosing cholangitis; WD = Wilson’s disease